190 related articles for article (PubMed ID: 38145840)
1. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract][Full Text] [Related]
2. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
[TBL] [Abstract][Full Text] [Related]
3. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
[No Abstract] [Full Text] [Related]
6. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
8. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Pettorruso M; Guidotti R; d'Andrea G; De Risio L; D'Andrea A; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; De Filippis S; Di Nicola M; Andriola I; Marcatili M; Nicolò G; Martiadis V; Bassetti R; Nucifora D; De Fazio P; Rosenblat JD; Clerici M; Maria Dell'Osso B; Vita A; Marzetti L; Sensi SL; Di Lorenzo G; McIntyre RS; Martinotti G;
Psychiatry Res; 2023 Sep; 327():115378. PubMed ID: 37574600
[TBL] [Abstract][Full Text] [Related]
10. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC
Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754
[TBL] [Abstract][Full Text] [Related]
13. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
Capuzzi E; Caldiroli A; Capellazzi M; Tagliabue I; Marcatili M; Colmegna F; Clerici M; Buoli M; Dakanalis A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502248
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
[TBL] [Abstract][Full Text] [Related]
16. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
[TBL] [Abstract][Full Text] [Related]
17. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
[No Abstract] [Full Text] [Related]
18. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
[TBL] [Abstract][Full Text] [Related]
20. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
Moaddel R; Luckenbaugh DA; Xie Y; Villaseñor A; Brutsche NE; Machado-Vieira R; Ramamoorthy A; Lorenzo MP; Garcia A; Bernier M; Torjman MC; Barbas C; Zarate CA; Wainer IW
Psychopharmacology (Berl); 2015 Jan; 232(2):399-409. PubMed ID: 25056852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
